Table 1. Baseline characteristics in KorAHF registry, EMPEROR-Reduced and EMPEROR-Preserved trial patients.
| Variables | KorAHF-HFrEF (n = 3,108) | EMPEROR-Reduceda (n = 3,730) | KorAHF-HFpEF (n = 2,070) | EMPEROR-Preserved (n = 5,988) | |
|---|---|---|---|---|---|
| Demographics | |||||
| Age, yr | 66.1 ± 14.8 | 66.5 ± 11.2 | 71.6 ± 13.3 | 72.0 ± 9.0 | |
| Women, % | 39.4 | 24.4 | 58.1 | 45.0 | |
| Asian race, % | 100.0 | 18.1 | 100.0 | 14.0 | |
| Body mass index, kg/m2 | 23.2 ± 3.8 | 27.8 ± 5.3 | 23.7 ± 4.0 | 30.0 ± 6.0 | |
| Co-morbidities, %b | |||||
| Hypertension | 58.6 | 72.3 | 67.3 | 90.0 | |
| Diabetes mellitus | 41.6 | 49.8 | 35.6 | 49.0 | |
| Chronic kidney disease | 25.8 | - | 23.0 | 50.0 | |
| Coronary artery disease | 37.8 | - | 32.2 | 35.0 | |
| Atrial fibrillation/flutter | 39.2 | 37.8 | 53.7 | 52.0 | |
| COPD | 10.6 | - | 11.8 | 13.0 | |
| Malignancy | 8.6 | - | 7.3 | 10.0 | |
| ICD | 3.5 | 31.8 | 2.0 | 4.0 | |
| NYHA functional class, % | |||||
| I | 0 | 0 | 0 | 0 | |
| II | 13.8 | 75.0 | 17.8 | 82.0 | |
| III | 37.5 | 24.4 | 37.2 | 18.0 | |
| IV | 48.6 | 0.6 | 45.0 | 0.3 | |
| Left ventricular ejection fraction, % | 27.1 ± 7.7 | 27.2 ± 6.1 | 54.0 ± 8.9 | 54.0 ± 9.0 | |
| Heart rate, bpm | 77.7 ± 14.0 | 71.5 ± 11.8 | 75.5 ± 14.2 | 70.0 ± 12.0 | |
| Systolic blood pressure, mmHg | 112.8 ± 16.9 | 121.4 ± 15.4 | 118.0 ± 18.1 | 132.0 ± 16.0 | |
| Diastolic blood pressure, mmHg | 67.1 ± 11.3 | - | 67.1 ± 11.8 | 76.0 ± 11.0 | |
| NT-proBNP, pg/mL | 3,866 (1,670–9,136) | 1,926 (1,153–3,525) | 2,412 (1,073–5,495) | 974 (499–1,730) | |
| Estimated glomerular filtration rate | |||||
| Mean value, mL/min/1.73 m2 | 70.2 ± 29.7 | 62.2 ± 21.5 | 69.2 ± 28.6 | 60.6 ± 19.8 | |
| Value of < 60 mL/min/1.73 m2, % | 35.4 | 48.6 | 35.6 | 49.9 | |
| Hemoglobin, g/dL | 12.4 ± 2.2 | - | 11.7 ± 2.0 | 13.0 ± 2.0 | |
| Hemoglobin A1c, % | 6.8 ± 1.4 | - | 6.6 ± 1.3 | 7.3 ± 1.5 | |
Continuous data presented as mean ± standard deviation or median (interquartile range), as appropriate. Categorical data presented as proportions. Vital signs and laboratory parameters were from at discharge (only hemoglobin A1c were collected at admission).
COPD = chronic obstructive pulmonary disease, EMPEROR-Preserved = EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction, EMPEROR-Reduced = EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction, HFpEF = heart failure with preserved ejection fraction, HFrEF = heart failure with reduced ejection fraction, ICD = implantable cardioverter–defibrillator, KorAHF = Korean Acute Heart Failure, NT-proBNP = N-terminal pro-B type natriuretic peptide, NYHA = New York Heart Association.
aDemographics and clinical characteristics of EMEPEROR-Reduced were based on the placebo group.
bIncludes in-hospital diagnoses.